Key result
This review provides an overview of recent advances in the diagnosis, prognosis, and management of heart failure with reduced ejection fraction, including biomarkers, novel therapies, and telemonitoring.
This review summarizes emerging diagnostic and therapeutic advances for HFrEF, including novel biomarkers, pharmacological therapies, mechanical support, and telemonitoring.
May inform HFrEF care updates; leaves open prospective validation of biomarkers and telemonitoring.
The purpose of this review is to provide an overview of diagnosis, prognosis and management of heart failure (HF) with reduced ejection fraction (HFrEF). Specifically, this review is divided into three sections. The first section will address biomarkers. The discovery of biomarkers has allowed further understanding of the pathophysiology of HF and provides insight into potential therapeutic targets. This review will focus on novel applications of natriuretic peptides (NPs) in clinical trials. Next, emerging biomarkers of HF, such as ST2, galectin-3 and copeptin, will be discussed. The second section aims to highlight HF therapies, including novel drugs and durable devices. The last section will review home haemodynamic monitoring and mobile health. We aim to provide context for the understanding of novel diagnostic and therapeutic advances in HF that are still in phase II or III trials, and have yet to become widely available.
No takes yet. Share an insight, caveat, or question.
Moayedi et al. (2017) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Biomarkers, emerging pharmacological therapies, durable mechanical support, and telemonitoring was evaluated. This review provides an overview of recent advances in the diagnosis, prognosis, and management of heart failure with reduced ejection fraction, including biomarkers, novel therapies, and telemonitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: